Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06263920

Neurofrailty: A Study of Late-onset Epilepsy and Its Associations

There is not much known about why some people develop seizures in adulthood, but some researchers think that it might be a warning from the body to highlight something may be wrong with the brain. A small number of people with first seizure in adulthood go on to experience problems like stroke or dementia later in life. However, stroke and dementia are common diseases, so it is not know whether there is a real association between these conditions. When people develop their first seizure in adult life, this is sometimes called Late-Onset Epilepsy. The NeuroFrailty study, will observe 'brain health' over the years following the onset of a seizure, to provide more information about people with these kinds of seizures.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Lancashire Teaching Hospitals NHS

Preston, Lancashire, PR2 9HT, United Kingdom

Location status: Recruiting

Location contact

Jasmine Wall

PRINCIPAL_INVESTIGATOR

Kina Bennett

CONTACT

[email protected]

(+44) 01772 522031

Research Access

CONTACT

[email protected]

About this study

The NeuroFrailty study involves observing people from the time of diagnosis of first seizure. It will look at investigations such as blood tests, blood pressure, brain scans, alongside other diagnoses to compare difference to people without seizures. The study will also review some participants to look in greater depth at lifestyle including exercise, driving, family planning, and memory assessments.

The study will review how changes occur over a number of years: for example whether there are changes in memory, new diagnoses, medication changes and how lifestyle has changed. Because there is so little research in this area, it is very difficult to predict what might happen. For example, some people can experience worse memory because of medication side effects; on the other hand, good seizure control following a diagnosis can sometimes lead to improved memory. Over years, it may become clear that some diseases are more likely in people with late-onset epilepsy than in people without such a diagnosis.

Purpose and Background

Some researchers think there may be a connection between epilepsy which starts in adulthood, and increased risk of stroke or dementia in the future. However, there is very little research or evidence in this area.

This study is an observational study, which means that the management of participants' seizure disorder will not be affected if they choose to take part in this study. The purpose of this study is to watch participants over the course of several years, to find out more about seizures which start in adulthood.

Participants can choose the level of involvement that is right for them.

  • LOW involvement. A researcher will check hospital and General Practice (GP records) once or twice per year, for the limited and specific purpose of checking: medications, any new diagnoses, investigations associated with stroke risk (such as cholesterol, blood pressure, heart trace) and any brain scans that have been performed.
  • HIGH involvement. This involves being contacted by telephone once per year for 15-30 minutes to ask questions assessing memory and enquiring about lifestyle, such as exercise, smoking and alcohol use.
  • VERY HIGH involvement. These participants will be contacted for a longer telephone conversation 30-45 minutes once per year about their experience of how epilepsy has affected home life, work and medications.

Glossary Seizure disorder = any disorder which involved having experienced at least one seizure. First seizure and epilepsy both can be classed as a form of seizure disorder.

Neurofrailty = A condition whereby a person is at risk of stroke or dementia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for case participants includes:

  • diagnosis of LOE or first seizure after the age of 18.
  • diagnosis confirmed or established at a tertiary neurology centre.
  • sequential cases will be used; in the unlikely event that eligible cases outstrip capacity, an annual cap of the first 150 patients per year per cohort will be used.

Inclusion criteria

for control participants includes:

  • established diagnosis of migraine.
  • with or without therapeutic medications with antiepileptic properties.

Exclusion criteria

Exclusion criteria

for case participants includes:

  • a 'lesional' attributable cause for seizures including malignancy, stroke (excluding transient ischaemic attack), hypoxic brain injury, trauma, vascular or congenital abnormality of likely aetiological significance.
  • people with migraine or headache syndrome can be included in case group - the presence or absence of a seizure syndrome is mutually exclusive between case and control groups, not the presence or absence of migraine.

Exclusion criteria

for control participants includes:

  • diagnosis of epilepsy or confirmed seizure.
  • 'lesional' attributable cause for seizures including malignancy, stroke (excluding transient ischaemic attack), hypoxic brain injury, trauma.

Treatment and study plan

Primary outcomes

  1. At the time of onset, do people with late-onset epilepsy have higher prevalence of cerebrovascular disease risk factors compared to a control population?

    Time frame: 3 years

    Including HbA1c, hypertension / blood pressure, total cholesterol, triglycerides, MRI changes

  2. Quality of Life - how of chronic illness is mediated

    Time frame: 3 years

    How is the experience of chronic illness in LOE mediated through the immediate experience of seizures (holidays, swimming), socioeconomic factors (unemployment, insurance, driving, family planning) and long-term risk of associated comorbidity

Secondary outcomes

  1. What is the absolute and relative incidence of stroke and dementia in people after the onset of LOE compared to the background population?

    Time frame: 3-5 years

    As described

  2. Which anti-epileptic drugs are used in current practice in LOE, and how are they tolerated?

    Time frame: 3 years

    As described

Study contacts

Contact information is provided by the study sponsor or research team.

Jasmine Wall, MB BChir

CONTACT

[email protected]

via switchboard

Sponsors and collaborators

Lead sponsor

Lancashire Teaching Hospitals NHS Foundation Trust

Other

Registry information

Official study title

A Prospective Population-based Longitudinal Observational Cohort Study of Late-onset Epilepsy, and Subsequent Stroke and Dementia.

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Feb 16, 2024
Registry last updated
Apr 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.